Apolipoprotein measurements: is more widespread use clinically indicated?

Area of Science:

• Cardiology
• Metabolic Syndrome Research
• Lipidology

Background:

• Apolipoprotein B (apo B) may be a more sensitive indicator of atherogenicity and cardiovascular risk than LDL-C.
• Conditions like diabetes and metabolic syndrome often feature normal LDL-C but elevated small, dense LDL particles, indicating higher apo B levels.

Purpose of the Study:

• To evaluate the utility of apo B as a refined measure for cardiovascular risk assessment.
• To discuss the recent recommendation for incorporating apo B as a therapeutic target in high-risk populations.

Main Methods:

• Review of current clinical data on apo B and its association with cardiovascular risk.
• Analysis of consensus recommendations from major medical organizations regarding apo B targets.

Main Results:

• Apolipoprotein B is proposed as a superior marker for atherogenicity compared to LDL-C.
• Consensus guidelines now recommend apo B as a therapeutic target for high-risk patients, with suggested goals < 90 mg/dL (high risk) and < 80 mg/dL (highest risk).
• Intensive statin therapy demonstrates efficacy in lowering apo B to meet these targets.

Conclusions:

• Apo B provides a more refined assessment of cardiovascular risk, particularly in patients with diabetes or metabolic syndrome.
• Targeting apo B levels represents a potential advancement in managing cardiometabolic risk.
• Further research is needed on the apo B/apo A-I ratio and the impact of HDL modulation on outcomes.